Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.85 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.85 |
| ▸ | CA1 | P00915 | 1/20 | 0.85 |
| ▸ | CA2 | P00918 | 1/20 | 0.85 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.85 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.85 |
| ▸ | ITGAL | P20701 | 1/20 | 0.85 |
| ▸ | CA4 | P22748 | 1/20 | 0.85 |
| ▸ | CA6 | P23280 | 1/20 | 0.85 |
| ▸ | ADK | P55263 | 1/20 | 0.85 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL6386255 | 0.92 | AHR (0.90) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL29352896 | 0.92 | — | — | |
| Indole SCHEMBL30463845 | 0.92 | — | — | |
| Indole SCHEMBL1160186 | 0.92 | AHR (1.00) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL698 | 0.92 | — | — | |
| Indole SCHEMBL30250492 | 0.92 | — | — | |
| Indole SCHEMBL28071644 | 0.92 | AHR (1.00) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL8213935 | 0.90 | AHR (0.85) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL15007820 | 0.90 | AHR (0.85) | AHRTRPA1CA1CA2ITGB2 | |
| Indole SCHEMBL2769465 | 0.90 | AHR (0.85) | AHRTRPA1CA1CA2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656395-A | Synthetic method of 2, 3-diaminoindole compound | 南京林业大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-101652346-B | Indole derivatives, process for their preparation and their use, especially as antibacterial agents | UNIV JOSEPH FOURIER | 2013-10-30 | — | — | CN | disclosed |
| CN-101652346-A | Novel indole derivatives, process for their preparation and their use, especially as antibacterial agents | UNIV JOSEPH FOURIER FR | 2010-02-17 | — | — | CN | disclosed |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1003739-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009025-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES INTERACTING WITH THE DOPAMINE D4 RECEPTOR | PFIZER PRODUCTS INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0421946-B1 | 3-indolepyruvic acid derivatives their method of production and therapeutic use | POLIFARMA SPA (IT) | 1996-11-20 | — | — | EP | disclosed |
| US-5210215-A | Reacting indoles, dimethylamine and formaldehyde to gramines, condensing with malonic compounds to tryptophans, converting to 3-indolepyruvic acids; also preparation from indoles by reaction with alkyl ester oximes of 3-bromopyruvic acid | POLIFARMA S.P.A. (IT) | 1993-05-11 | — | — | US | disclosed |
| EP-0421946-A2 | 3-indolepyruvic acid derivatives their method of production and therapeutic use | POLIFARMA S.p.A. (IT) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | DRD2, DRD3, DRD4 | AHR 188/4885TRPA1 1002/4885CA1 4707/4885 |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | DRD2, DRD3, TPH1 | AHR 135/4885TRPA1 2381/4885CA1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.